Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses

Kathleen Puntillo, RN, PhD¹ and Ramana K. Naidu, MD²

Abstract

Background: Chronic pain associated with serious illnesses is having a major impact on population health in the United States. Accountability for high quality care for community-dwelling patients with serious illnesses requires selection of metrics that capture the burden of chronic pain whose treatment may be enhanced or complicated by opioid use.

Objective: Our aim was to evaluate options for assessing pain in seriously ill community dwelling adults, to discuss the use/abuse of opioids in individuals with chronic pain, and to suggest pain and opioid use metrics that can be considered for screening and evaluation of patient responses and quality care.

Design: Structured literature review.

Measurements: Evaluation of pain and opioid use assessment metrics and measures for their potential usefulness in the community.

Results: Several pain and opioid assessment instruments are available for consideration. Yet, no one pain instrument has been identified as “the best” to assess pain in seriously ill community-dwelling patients. Screening tools exist that are specific to the assessment of risk in opioid management. Opioid screening can assess risk based on substance use history, general risk taking, and reward-seeking behavior.

Conclusions: Accountability for high quality care for community-dwelling patients requires selection of metrics that will capture the burden of chronic pain and beneficial use or misuse of opioids. Future research is warranted to identify, modify, or develop instruments that contain important metrics, demonstrate a balance between sensitivity and specificity, and address patient preferences and quality outcomes.

Keywords: accountability; chronic pain; opioid use; serious illness; symptom assessment; symptom control

Introduction

APPROXIMATELY 100 MILLION ADULTS in the United States, or from 11% to 40%, report chronic pain.^{1,2} The estimated economic cost is from \$560 to \$635 billion for necessary healthcare and lower worker productivity.^{3,4} Chronic pain is often associated with serious illnesses: conditions associated with a high risk of mortality, impaired

quality of life, restricted function, high symptom and/or treatment burden, and caregiver stress.⁵ Using pain assessment information, treatment decisions are made, preferably within the context of the patient's associated illnesses, functional status, and quality-of-life goals.

One standard analgesic treatment for moderate-to-severe pain is use of opioids. While opioids are often successful in minimizing pain, it is incumbent upon treating health

¹Department of Nursing, University of California, San Francisco, San Francisco, California.

²Division of Pain Medicine, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California.

Accepted August 22, 2017.

This article was developed for, and discussed at, a meeting titled “A Convening on Quality Measures for Serious Illness Care,” which was held May 9–11, 2017 in Banff, Canada. The meeting was organized by the Gordon and Betty Moore Foundation, the Cambia Palliative Care Center of Excellence at the University of Washington, the Center to Advance Palliative Care, and the Icahn School of Medicine at Mount Sinai. This supplement is funded by the Gordon and Betty Moore Foundation.

professionals to be concerned about their potentially serious adverse consequences such as injury, dependence, addiction, and death. Indeed, the current opioid epidemic and associated increased death rates have highlighted these concerns.² Consideration of opioid use risk is an essential element for determining accountability for high-quality care delivery to community-dwelling patients with serious illnesses. This article has three aims: (1) to present options for assessing pain in seriously ill community dwelling adults according to their ability to communicate by proposing pain metrics that are effective representations of the patient's condition; (2) to discuss the use of opioids, as appropriate, and their intended and unintended consequences, in patients with serious illnesses; and, (3) to suggest accountability measures for use during pain treatment that can promote quality care and minimize adverse consequences in seriously ill patients.

Assessing and Recording Chronic Pain Metrics

Defining and classifying chronic pain through use of pain metrics

Metrics that define and classify chronic pain provide a focus for professional interventions and evaluation of quality of care. Selecting quality pain metrics requires answers to these questions: (1) what pain metrics are necessary for a screening examination to identify pain? (2) will the patient have the capacity to provide information about the pain metrics, or will input from a patient's family member, surrogate, or health professional be necessary? (3) if a screening examination is positive for chronic pain, what pain metrics are necessary to capture the dimensions, burdens, and impact of pain on the seriously ill patient and response to treatment?

The definition of pain has evolved over the years but still retains the characteristic of being a distressing experience associated with actual or potential tissue damage. (See Table 1 for a glossary of terms.) Pain is recognized as having sensory, emotional, cognitive, and social components, the latter making pain a shared experience. Chronic pain, when described by a time frame, is that which persists past the normal time of healing or lasting at least three months.⁶ When chronic, or persistent, pain is associated with substantial restriction of participation in work, social, and self-care activities for six months or more, it is identified as high impact chronic pain.⁷ However, looking beyond a time framework for classifying chronic pain, consideration must be given to the mechanisms and burden of pain⁸ and recognize that pain classification can evolve over time and new discoveries.⁹ Indeed, a new classification is currently under development.¹⁰

Pain metrics

The important characteristics and domains of pain are identified by instruments and systems with specific pain metrics. (See Table 2 which outlines the relationship among pain domains, metrics, and instruments.) Pain domains as targets for assessment can include pain's sensory and affective qualities, its temporal characteristics, its location and bodily distribution, pain behaviors, and psychological impact on function.^{1,11,12} Ascertaining the details of a patient's pain relies on a patient's ability to reliably communicate their pain experience and to access individuals and systems that capture

TABLE 1. GLOSSARY OF TERMS

Definition

- Serious illness: "Serious illness" is a condition that carries a high risk of mortality, negatively impacts quality of life and daily function, and/or is burdensome in symptoms, treatments, or caregiver stress.⁵
- Pain: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.⁴¹
- Pain (updated): An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. The inability to communicate verbally does not negate the possibility that an individual is experiencing pain and is in need of appropriate pain-relieving treatment.⁴²
- Pain (suggested modification): Pain is a distressing experience associated with actual or potential tissue damage with sensory, emotional, cognitive, and social components.⁴³
- Chronic pain, when described by a time frame, is that which persists past the normal time of healing or lasting at least three months.⁶
- High impact chronic pain: persistent pain with substantial restriction of participation in work, social, and self-care activities for six months or more.¹
- Nociceptive pain: Pain that arises from actual or threatened damage to non-neural tissue and is due to the activation of nociceptors.⁴²
- Neuropathic pain: Pain resulting from a lesion or dysfunction of the peripheral or central nervous systems.⁴²
- Pain behaviors: Various actions observed in an individual by others that may indicate that pain is present. These may include language, vocalizations, facial expression, body posture, and escape or avoidance actions.²³
- Medication abuse is self-administration of medications to alter or enhance one's state of consciousness.^{37,44} This is an intentional maladaptive pattern of use of a medication (whether legitimately prescribed or not) leading to significant impairment or distress.
- Medication misuse is defined as not taking a medication exactly as prescribed, for example, being prescribed an opioid for pain after ankle surgery but using it for headaches well after the surgical healing period.^{45,46}
- Medication addiction is defined as a primary chronic disease of brain reward, motivation, memory, and related circuitry.⁴⁷ Dysfunction in these circuits leads to characteristic biological, psychological, social, and spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by substance use and other behaviors. Addiction is characterized by inability to consistently abstain, impairment in behavioral control, craving, diminished recognition of significant problems with one's behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature death.

pain information. A comprehensive pain assessment would optimally include use of metrics for each domain, while a screening pain assessment would be more focused. Providers are required to gather "enough information" to make treatment decisions and evaluate outcomes for which they are

TABLE 2. CLINIMETRICS FOR CHRONIC PAIN ASSESSMENT

Tools with specific metrics	Pain domain measured ^a									
	Sensory ^a	Temporality ^a	Relief ^a	Location ^a	Interference/ functional impact ^a	Affective	Evaluative	Psychosocial impact	Behavioral ^b	Comments
VAS, NRS, VRS	x					x				Separate scales used for each dimension, sensory, and affect
BPI-SF	x		x		x					
MPQ-SF	x			x		x	x			
PEG	x				x			a		Pain intensity, enjoyment of life, interference with general activity
PROMIS PD-Q	x	x		x radiating	x (6 items)				x (7 items)	7 questions on sensations; 4 on course patterns; 1 on radiating
PAINAD									x	
PACSLAC									x	
DOLOPLUS-2									x	
MOBID									x	
NATIONAL HEALTH INTERVIEW SURVEY	x	x		x	x				x	Interference with life and work activities
PROMIS	x				x				x	Other nonpain items can be added such as depression and sleep
RAI	x				x				x	

^aThe first five domains on left represent those deemed most important, in order of importance, by Palliative Care clinician experts.²⁸

^bBehaviors for nonself-reporting patients.

BPI-SF, Brief Pain Inventory-Short Form; DOLOPLUS-2, Abbreviation for a French-language scale; MOBID, Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale; MPQ-SF, McGill Pain Questionnaire-Short Form; NRS, numeric rating scale; PACSLAC, Pain Assessment Checklist for Seniors with Limited Ability to Communicate; PAINAD, Pain Assessment in Advanced Dementia Scale; PD-Q, painDETECT questionnaire; PEG, Pain Intensity, Enjoyment, General Activity; PROMIS, Patient-Reported Outcomes Measurement Information System; RAI, Resident Assessment Instrument; VAS, visual analog scale; VRS, verbal rating scale.

accountable. Gathering pain data from community dwelling individuals with serious illnesses may require a triaging process that begins with more simple interrogations.

Unidimensional pain measures and short questionnaires

Simple interrogations generate data from use of unidimensional measures and brief questionnaires by patients who can self-report and/or self-record. Well validated unidimensional numeric rating scale (NRS) and visual analog scale (VAS) are often used to quantify degree of pain intensity and, less often, degree of pain distress.¹³ However, simply focusing on a pain intensity number provided by patients with chronic pain can be problematic since one number does not reflect the total burden of chronic pain. A decrease in a number may not serve as a metric of treatment outcome success¹⁴; nor can chronic pain treatment be unsuccessful even when a pain intensity number does not change.¹⁵

There are a number of brief questionnaires that focus on multidimensional domains of pain: the Brief Pain Inventory (BPI), the Short Form-McGill Pain Questionnaire (SF-MPQ), the PEG, and the painDETECT. The BPI is a short self-administered questionnaire that assesses pain severity, as well as its impact on function.¹⁶ The BPI-Short Form (BPI-SF) has been used to identify characteristics of breakthrough pain in patients with cancer-related pain in remission.¹⁷ The SF-MPQ is also a self-administered questionnaire that addresses sensory, affective, and cognitive (evaluative) domains of pain¹⁸ and correlates highly with the well validated Long Form-MPQ.¹⁹ The PEG is a 3-item scale that measures pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G).²⁰ It has been tested against the BPI for reliability and content validity and has been shown responsivity to clinical interventions.²¹ Recent Center for Disease Control (CDC) Guidelines² offer the PEG as one example of an instrument to assess treatment outcomes. Finally, the painDETECT questionnaire (PD-Q) evaluates symptoms associated with neuropathic versus nociceptive pain. Since patients with neuropathic pain often suffer more severely than patients with nociceptive pain,²² a tool such as the PD-Q may help with better diagnosis and treatment.

Behavioral pain measures

Some patients with serious illnesses are unable to self-report their pain due to impaired cognitive capacity associated with delirium, dementia, and/or somnolence. Assessing behavioral indices as proxy measures of pain can help to identify people with chronic pain and make them more likely to receive therapeutic interventions.

Pain behaviors noted by healthcare workers in patient medical records in a palliative care center included patient vocalizations such as moans or groans or crying out; facial expressions such as grimaces and winces; and actions such as holding a body part and clenching fists.²³ Recognition of these behaviors in a palliative care population may assist with development and validation of a pain behavior tool for seriously ill patients in those and other settings. One such tool is the MOBID scale (Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale).²⁴ The MOBID has been tested in nondelirious, nonpsychotic nursing home patients

with dementia suspected to have chronic pain of >3 on a 0–10 NRS intensity scale. Researchers identified the following: pain behaviors were more frequently observed during mobility than rest; observer-generated NRS pain intensity scores and number of behaviors observed were positively correlated; and the best agreement between the testers was for pain noises, although facial expression was demonstrated most frequently. Observation and recording of behaviors by family members or health professionals that may indicate pain deserve careful consideration as a metric-generating activity in seriously ill community-based patients unable to reliably self-report.

Several other pain behavior scales have been developed for older persons with severe cognitive impairment, such as the PAINAD, PACSLAC, and the DOLOPLUS-2 (see footnote of Table 2 for full name of scales). Psychometric properties of these three scales were tested in Dutch nursing home residents.²⁵ The PACSLAC had better psychometric attributes and was found to be more “user friendly” to raters than the other two scales. However, the testing paradigm was acute (vaccination) pain rather than chronic pain. Items on the PACSLAC and PAINAD could be examined for their applicability to a newly constructed behavioral assessment scale that may reflect chronic pain in persons with serious illnesses.

Use of electronic healthcare data to assess pain and its impact on the person

von Korff et al.¹ pilot tested a 25-item electronic pain survey in a sample of patients in a large group health plan in Washington, with most items derived from established questionnaires. Answers to three specific questions allowed for categorization of respondents as persons with high-impact chronic pain (14% of 365 respondents) versus those with moderate-impact chronic pain (19% of respondents.) There were clear differences between the two groups in responses to survey questions regarding frequency of healthcare use, level of pain intensity, level of life interference, and higher number of painful body sites. This led to researcher confidence that responding to questions on an electronic health survey would be feasible and beneficial in identifying primary care, population-based patients with moderate-to-high impact chronic pain.

A second electronic database, Patient-Reported Outcomes Measurement Information System (PROMIS),²⁶ was developed by academic scientists, primarily for research purposes, from several institutions and the NIH as a computerized bank of measures of patient symptoms, functional status, and quality of life. There is a pain intensity question as part of a global health scale, and there are two pain measures, pain behavior (a 7-item short form) and pain interference (a 6-item short form), that showed good reliability and validity. The PROMIS short form was a less sensitive measure of pain interference than the BPI or the PEG when used with patients with moderate musculoskeletal pain.²¹ Nevertheless, PROMIS has shown to be efficient, flexible, and precise; its item bank is available for public use and items can be made part of an Internet survey platform.²⁶

A third large electronic database is one used in nursing homes certified by Medicare and Medicaid to assess residents' strengths and needs through comprehensive

One important avenue of exploration is the role of opioid therapy for seriously ill patients with chronic pain. It is essential to consider that all pains are not equal; there are some conditions that are opioid responsive; some that may be; and others for which opioids are not indicated. Recent CDC Guidelines² recommend that prescribers reconsider the use of opioids for chronic noncancer pain, leading to an increased awareness of patients of the dangers of opioids. However, they fall short in providing guidance for use in patients with cancer or other serious illnesses. In addition, Baker³⁰ warns that care should be taken in establishing new standards, as is being done by The Joint Commission, to avoid the risk of moving the care pendulum away from good pain management. Decreased opioid prescribing may leave a subset of patients, such as those who are seriously ill, with no effective options to manage their unique chronic pain. For this reason, it is important that we continue to gather evidence to determine condition-specific guidelines for pain management. According to recent Clinical Practice Guidelines from the American Society of Clinical Oncology,³¹ consideration

FIG. 2. Number of deaths related to opioids per year in the United States 2000–2015. CDC Wonder Data. Stratification based on opioid type: Natural and Semi-Synthetics (e.g., morphine, hydromorphone), Methadone, Synthetics excluding Methadone (e.g., fentanyl, carfentanil), Heroin, and All Opioids. CDC, Center for Disease Control.

should be given to the use of nonopioid and adjuvant analgesics for chronic pain in patients with cancer. The Guidelines note that, for patients who do not respond to these more conservative measures and have continued distress and impairment of function, a trial of opioids can be considered. While they are not effective for many conditions,³² there is evidence to identify when opioids should and should not be used, even within the context of serious illness.³³ It is essential to consider metrics to evaluate the effectiveness of opioids, as well as the risks of their use, especially considering the current opioid epidemic.

Balancing the use and misuse of opioids

Determining if an opioid is effective and if a patient is using an opioid appropriately requires considerable vigilance and time.^{34,35} While opioids can diminish suffering for those in pain, their abuse, misuse, and addiction potential (see Table 1 for definitions) can impact community and population health. Figure 1 provides an algorithm for a screening or a comprehensive assessment of pain and opioid use. The CDC has demonstrated that opioid-related deaths have been increasing over the past 10 years (Fig. 2) with much of the increase attributable to increasing opioid prescriptions. Currently, the estimation is that 3–20% of patients prescribed an opioid will be addicted.^{2,36} However, rather than stigmatizing individuals who are susceptible to opioid addiction, monitoring and instituting a shared plan for aiding individuals who do become addicted is necessary.

Assessing the risk/benefit ratio of treating pain with opioids

Provider education of patients regarding the myriad risks of opioids is time consuming. The patient–provider rela-

tionship in American medicine has been affected by multiple forces, including managed care, medicine as a business, and shortened physician visits leading to quick decision making. Yet a shared decision-making model of medicine is paramount when it comes to the complex issue of opioid management. Assessing risk for opioid misuse can help providers understand how their patients may fare with potentially abusive and addictive substances. Guidelines suggest that clinicians take a “universal precautions” approach to minimize adverse consequences of opioid use³¹ (p. 3339). The beneficial effects of opioids are important to note: improved function in activities of daily living, decreased pain severity, decreased pain interference, and improved quality of life. Clinicians must also recognize the risks of opioid therapy with an individual patient. Table 3 provides a checklist of opioid therapy risks. In addition, clinicians can use specific opioid risk screening tools to assess risk based on substance use history, general risk taking, and reward-seeking behavior. There are several screening tools specific to the assessment of risk in opioid management that can be incorporated into a community-based assessment of chronic pain and opioid use^{37–39} (Table 4). Research is still needed on continued psychometric evaluation of these existing and newly developed instruments and the effects of their use in evaluating clinical outcomes.⁴⁰

Determining Accountability for Quality Care: Selecting Pain and Opioid Metrics

Determining accountability for quality care of patients with serious illness who have chronic pain is complex. Selection of pain metrics is a context-dependent process depending on the patient’s ability to report their pain; whether patients are in primary care, managed care, or residential care and; what type of data is required by health systems and

TABLE 3. SCREENING TOOLS FOR OPIOID MISUSE

Opioid Risk Tool. ⁴⁸	ORT	Brief self-assessment for patients with chronic pain being considered for opioid therapy. Tested on new patients treated in a pain clinic. Ten weighted risk items. Good sensitivity and specificity.
Screening and Opioid Assessment for Patients with Pain—Revised. ⁴⁹	SOAPP-R	Revised, shorter version of original (decreased from 142 to 24 items.) Intended for use with persons with chronic pain. Screens risk for aberrant medication-related behavior. Good reliability and validity.
Screening Instrument for Substance Abuse Potential. ⁵⁰	SISAP	Assesses risk of opioid dependency in those with substance abuse history. Contains five items. Good sensitivity and specificity. Used by primary care providers. Not validated by pain patients.
Current Opioid Misuse Measure. ⁵¹	COMM	For pain patients already on long-term opioid therapy. Used to assess adherence to opioid prescribing. Tested on 277 patients with chronic noncancer pain. 17 items. Adequately measures aberrant behavior, excellent internal consistency, and test-retest reliability.

funding agencies to address their outcomes of interest. Quality outcomes of interest would include whether pain was identified through proper screening and comprehensive assessments and that the patient's relief from pain and their quality of life and functional capacity are improved with pain treatment.³¹ Table 2 provides a grid of pain instruments that can be considered according to whether pain self-report is an option or whether proxy observation of patients' behaviors

is required. Quality outcomes would include assessment of the appropriateness of pain treatment and treatment results. Ineffective or adverse results from treatment require accountability.

Measures of accountability regarding the use and effectiveness of opioids must take the particular patient's situation in mind. Clinician concern about the use of opioids can sometimes depend on their estimates of the patient's life expectancy, being less concerned with patients in hospice settings and more concerned with patients who have a longer course of treatment. Nevertheless, clinicians' decision making regarding opioid use, especially with their attendant risks and ongoing monitoring of the balance of their effectiveness and risks, should be transparent. Table 4 suggests opioid risk tools that can be used on an ongoing basis for patients with chronic pain receiving opioids, to identify special needs. Identifying, intervening, and evaluating intervention results can improve accountability and quality care. Figure 1 offers an algorithm for screening patients' pain and opioid use while identifying instruments for consideration.

TABLE 4. RISKS OF OPIOID THERAPY
(CHECK ALL THAT APPLY)

☐ Worse Pain over time (Hyperalgesia)
☐ Respiratory Depression
☐ Risk of Death with Obstructive and/or Central Sleep Apnea
☐ Nausea
☐ Vomiting
☐ Constipation
☐ Hives (Urticaria)
☐ Tremors
☐ Potential Harm to Unborn or Newborn Baby (if breastfeeding)
☐ Itching (Pruritus)
☐ Impairment while Driving or Operating Heavy Machinery
☐ Drowsiness (Sedation)
☐ Sweating
☐ Weight gain
☐ Depressed mood
☐ Seizures
☐ Low Testosterone
☐ Irregular/Absent Menstruation
☐ Decreased Bone Density
☐ Withdrawals
☐ Potential for Addiction
☐ Potential for Abuse
☐ Inability to Control Pain with Increasing Doses of Opioid (Tolerance)
☐ Altered Mental Status (Delirium)
☐ Risk of others Using/Stealing your drugs
☐ Arrhythmia (specific opioids)
☐ Combination of Opioids with Other Sedating Medications (Benzodiazepines or Muscle Relaxants) or Alcohol increases other risks listed
☐ Sudden Death

Conclusion

Accountability for high quality care for community-dwelling patients with serious illnesses requires selection of metrics that will capture the burden of chronic pain whose treatment may be enhanced or complicated by opioid use. Community-based care will need to be accountable through selection of, and attention to, appropriate pain and opioid metrics. Future research is warranted to identify, modify, or develop instruments that contain important metrics, demonstrate a balance between sensitivity and specificity, and, importantly, speak to the preferences of patients with serious illnesses.

Author Disclosure Statement

K.P., RN, PhD has no competing financial interests. R.K.N., MD receives honoraria from Abbott, Halyard Health, and Sonosite.

References

1. Von Korff M, Scher AI, Helmick C, et al.: United States national pain strategy for population research: Concepts, definitions, and pilot data. *J Pain* 2016;17:1068–1080.

2. Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. *Morb Mortal Wkly Rep* 2016;65:1–49.
3. Rudd RA, Aleshire N, Zibbell JE, Gladden M: Increases in drug and opioid overdose deaths—United States, 2000–2014. *Morb Mortal Wkly Rep* 2016;64:1378–1382.
4. Gaskin DJ, Richard P: The economic costs of pain in the United States. *J Pain* 2012;13:715–724.
5. Kelley AS: Defining “serious illness.” *J Palliat Med* 2014; 17:985.
6. International Association for the Study of Pain: Classification of Chronic Pain Second Edition, Revised. www.iasp-pain.org/PublicationsNews/Content.aspx?ItemNumber=1673&navItemNumber=677 (Last accessed August 15, 2017).
7. Department of Health & Human Services: National Pain Strategy: A comprehensive population health strategy for pain. 2017. https://iprcc.nih.gov/docs/HHSNational_Pain_Strategy.pdf (last accessed September 21, 2017).
8. Fillingim RB, Bruehl S, Dworkin RH, et al.: The ACTTION-American Pain Society Pain Taxonomy (AAPT): An evidence-based and multidimensional approach to classifying chronic pain conditions. *J Pain* 2016; 15:241–249.
9. Dworkin RH, Bruehl S, Fillingim RB, et al.: Multi-dimensional diagnostic criteria for chronic pain: Introduction to the ACTTION-American Pain Society pain taxonomy (AAPT). *J Pain* 2016;17:T1–T9.
10. Treede RD, Rief W, Barke A, et al.: A classification of chronic pain for ICD-11. *Pain* 2015;156:1003–1007.
11. Fillingim RB, Loeser JD, Baron R, et al.: Assessment of chronic pain: Domains, methods, and mechanisms. *J Pain* 2016;17(9 Suppl):T10–T20.
12. Turk DC, Fillingim RB, Ohrbach R, et al.: Assessment of psychosocial and functional impact of chronic pain. *J Pain* 2016;17(9 Suppl):T21–T49.
13. Jensen MP, Karoly P, Braver S: The measurement of clinical pain intensity: A comparison of six methods. *Pain* 1986;27:117–126.
14. Ballantyne JC, Sullivan MD: Intensity of chronic pain—The wrong metric? *N Engl J Med* 2015;373:2098–2099.
15. Sullivan MD, Ballantyne J: Reply. *Pain* 2016;157:1574–1575.
16. Cleeland CS: The Brief Pain Inventory. 1991. www.npcrc.org/files/news/briefpain_long.pdf (Last accessed March 20, 2017).
17. Katz NP, Gajria KL, Shillington AC, et al.: Impact of breakthrough pain on community-dwelling cancer patients: Results from the National Breakthrough Pain Study. *Postgrad Med* 2017;129:32–39.
18. Melzack R: The short-form McGill Pain Questionnaire. *Pain* 1987;30:191–197.
19. Caraceni A, Cherny N, Fainsinger R, et al.: Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. *J Pain Symptom Manage* 2002;23:239–255.
20. Krebs EE, Lorenz KA, Bair MJ, et al.: Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 2009; 24:733–738.
21. Kean J, Monahan PO, Kroenke K, et al.: Comparative responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale. *Med Care* 2016;54:414–421.
22. Freynhagen R, Baron R, Gockel U, et al.: The painDETECT project—Far more than a screening tool on neuropathic pain. *Curr Med Res Opin* 2016;32:1033–1057.
23. Gagliese L, Rodin R, Chan V, et al.: How do healthcare workers judge pain in older palliative care patients with delirium near the end of life? *Palliat Support Care* 2016; 14:151–158.
24. Husebo BS, Strand LI, Moe-Nilssen R, et al.: Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale (MO-BID): Development and validation of a nurse-administered pain assessment tool for use in dementia. *J Pain Symptom Manage* 2007;34:67–80.
25. Zwakhalen SM, Hamers JP, Berger MP: The psychometric quality and clinical usefulness of three pain assessment tools for elderly people with dementia. *Pain* 2006;126:210–220.
26. Cella D, Riley W, Stone A, et al.: The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J Clin Epidemiol* 2010;63:1179–1194.
27. Center for Medicare & Medicaid Services: Long-Term Care Facility Resident Assessment Instrument 3.0 User’s Manual. 2015.
28. Holen JC, Hjermstad MJ, Loge JH, et al.: Pain assessment tools: Is the content appropriate for use in palliative care? *J Pain Symptom Manage* 2006;32:567–580.
29. Hjermstad MJ, Gibbins J, Haugen DF, et al.: Pain assessment tools in palliative care: An urgent need for consensus. *Palliat Med* 2008;22:895–903.
30. Baker DW: History of The Joint Commission’s pain standards: Lessons for today’s prescription opioid epidemic. *JAMA* 2017;317:1117–1118.
31. Paice JA, Portenoy R, Lacchetti C, et al.: Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016;34:3325–3345.
32. Sjogren P, Gronbaek M, Peuckmann V, et al.: A population-based cohort study on chronic pain: The role of opioids. *Clin J Pain* 2010;26:763–769.
33. Passik SD, KirshKL: Opioid therapy in patients with a history of substance abuse. *CNS Drugs* 2004;18:13–25.
34. Coughlin DJ, Gainor C, Gaston CL, et al.: The opioid abuse and misuse epidemic: Implications for pharmacists in hospitals and health systems. *Am J Health Syst Pharm* 2014;71:1539–1554.
35. Brennan MJ, Stanos S: Strategies to optimize pain management with opioids while minimizing risk of abuse. *PM&R* 2010;2:544–558.
36. Barry DT, Irwin KS, Jones ES, et al.: Opioids, chronic pain, and addiction in primary care. *J Pain* 2010;11:1442–1450.
37. Volkow ND, McLellan AT: Opioid abuse in chronic pain—Misconceptions and mitigation strategies. *N Engl J Med* 2016;374:1253–1263.
38. Hahn KL: Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs. *Am Health Drug Benefits* 2011;4:107–114.
39. Kennedy AJ, Arnold RM, Childers JW: Opioids for chronic pain in patients with history of substance use disorders, Part 1: Assessment and initiation #311. *J Palliat Med* 2016; 19:888–889.

40. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009;10:113–130.
41. Pain terms: A list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. *Pain* 1979;6:249.
42. International Association for the Study of Pain: IASP Taxonomy. 2014. www.iasp-pain.org/Taxonomy (Last accessed February 27, 2017).
43. Williams AC, Craig KD: Updating the definition of pain. *Pain* 2016;157:2420–2423.
44. Meyer R, Patel AM, Rattana SK, et al.: Prescription opioid abuse: A literature review of the clinical and economic burden in the United States. *Popul Health Manag* 2014;17:372–387.
45. Strassels SA: Economic burden of prescription opioid misuse and abuse. *J Manag Care Pharm* 2009;15:556–562.
46. Thienprayoon R, Porter K, Tate M, et al.: Risk stratification for opioid misuse in children, adolescents, and young adults: A quality improvement project. *Pediatrics* 2017;139:e1–e10.
47. American Society of Addiction Medicine: Definition of Addiction. 2011. www.asam.org/quality-practice/definition-of-addiction (Last accessed March 20, 2017).
48. Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. *Pain Med* 2005;6:432–442.
49. Butler SF, Fernandez K, Benoit C, et al.: Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). *J Pain* 2008;9:360–372.
50. Clinical Tools, Inc.: The Screening Instrument for Substance Abuse Potential. www.opioidrisk.com/node/1397 (Last accessed March 27, 2017).
51. Butler SF, Budman SH, Fernandez KC, et al.: Development and validation of the Current Opioid Misuse Measure. *Pain* 2007;130:144–156.

Address correspondence to:
Kathleen Puntillo, RN, PhD
Department of Nursing
University of California, San Francisco
2 Koret Way, Box 0610
San Francisco, CA 94143-0610

E-mail: kathleen.puntillo@ucsf.edu